 |
|
|
| |
Dual, Triple, and Quadruple Combination Treatment with a Protease Inhibitor (GS-9256) and a Polymerase Inhibitor (GS-9190) alone and in Combination with Ribavirin (RBV) or PegIFN/RBV for up to 28 days in
Treatment Naïve, Genotype 1 HCV Subjects
|
| |
| |
Reported by Jules Levin
AASLD Nov 2 2010 Boston
AASLD: Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study - (11/01/10)
61st Annual Meeting of the American Association
for the Study of Liver Diseases
October 29 - November 2, 2010
Boston, Massachusetts, USA
Oral # LB-1
S Zeuzem,1 P Buggisch,2 K Agarwal,3 M Manns,4 P Marcellin,5
GR Foster,6 D Sereni,7 H Klinker,8 C Moreno,9 JP Zarksi,10 Y Horsmans,11 M Shelton,12 S West,12 J Zong,12 J Harris,12 J McHutchison,12 W Lee,12 W Delaney,12 D Oldach12.
1Medizinische Klinik I, Frankfurt, Germany; 2IFI Studien-und Projekte, Hamburg, Germany; 3Institute of Liver Studies, King's College Hospital, London, United Kingdom; 4Medizinische Hochschule Hannover, Zentrum fur Innere Medizin Klinikum der J.W. Goethe- Hannover, Germany; 5Service Hepatologie, Hopital Beaujon APHP, University of Paris Denis Diderot and INSERM CRB3, Clichy, France; 6Queen Mary University of London,United Kingdom; 7Hopital Saint-Louis, Service de Medecine Interne,Avenue Claude Vellefaux, Paris, France; 8Universitatsklinikum Wurzburg, Medizinische Klinik und Poliklinik II, Wurzburg, Germany; 9Department of Gastroenterology and Hepatopancreatology, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium; 10CHU de Grenoble - Hopital MichallonLa Tronche, France; 11 Gastroenterology Unit, Cliniques universitaires Saint-Luc, Universite catholique de Louvain, Bruxelles, Belgium; 12Gilead Sciences, Inc., Foster City, CA, USA.
|
| |
|
|
|
|
|
